Loading
Life sciences · Journal article
Current Oncology · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: This study evaluated long-term survival outcomes in breast cancer patients aged ≥80 years, focusing on how prognostic factors change when competing mortality risks are considered. Methods: We retrospectively analyzed 106 octogenarian breast cancer patients treated between 2013 and 2023. Endocrine therapy was evaluated as a treatment-related prognostic factor. Treatment-related prognostic factors were evaluated using multivariable Cox proportional hazards and Fine–Gray competing-risks models. Results: The median age was 82 years, and the median follow-up time was 27.5 months (range, 6–99 months). In the multivariable Cox proportional hazards, biopsy compared with surgery (HR, 0.56; p = 0.037), presence of endocrine therapy (HR, 0.38; p = 0.003), and CCI ≥8 (HR, 9.96; p < 0.001) were independently associated with OS. In the Fine–Gray model, the associations of surgical procedure (p = 0.120) and endocrine therapy (p = 0.081) with breast cancer-specific mortality were no longer statistically significant. CCI ≥8 remained significantly associated with breast cancer-specific mortality (sHR, 3.76; 95% CI, 1.52–9.31; p = 0.004). Conclusions: In octogenarian breast cancer patients, surgery and endocrine therapy were associated with improved OS, but their associations with breast cancer-specific mortality were attenuated after accounting for competing risks. High CCI emerged as the most robust prognostic factor. These findings support incorporating comorbidity burden and competing-risks assessment into individualized treatment decisions in this population.